United Therapeutics Co. (NASDAQ:UTHR) Position Boosted by Fisher Asset Management LLC

Fisher Asset Management LLC increased its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 3.1% during the fourth quarter, Holdings Channel reports. The firm owned 3,731 shares of the biotechnology company’s stock after purchasing an additional 112 shares during the period. Fisher Asset Management LLC’s holdings in United Therapeutics were worth $820,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. GAMMA Investing LLC acquired a new stake in shares of United Therapeutics during the 4th quarter valued at $43,000. C M Bidwell & Associates Ltd. acquired a new stake in shares of United Therapeutics during the third quarter worth $91,000. Blue Trust Inc. lifted its holdings in shares of United Therapeutics by 10.0% during the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 46 shares during the last quarter. CWM LLC boosted its position in shares of United Therapeutics by 45.7% in the 4th quarter. CWM LLC now owns 670 shares of the biotechnology company’s stock valued at $147,000 after purchasing an additional 210 shares during the period. Finally, Synovus Financial Corp purchased a new position in United Therapeutics in the 3rd quarter worth about $203,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Trading Up 1.9 %

NASDAQ:UTHR opened at $266.05 on Friday. The company has a market capitalization of $11.80 billion, a P/E ratio of 12.58 and a beta of 0.54. The stock’s 50 day moving average price is $239.87 and its 200 day moving average price is $230.35. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $268.21.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating the consensus estimate of $5.63 by $0.54. The company had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business’s revenue was up 33.7% compared to the same quarter last year. During the same period last year, the company earned $4.86 earnings per share. On average, research analysts forecast that United Therapeutics Co. will post 23.88 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $259.70, for a total transaction of $934,920.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $33,761. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $259.70, for a total transaction of $934,920.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $33,761. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total value of $3,548,850.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $30,756.70. The disclosure for this sale can be found here. In the last ninety days, insiders sold 147,630 shares of company stock worth $35,089,803. 12.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on UTHR shares. The Goldman Sachs Group lifted their target price on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Wedbush reissued an “outperform” rating and set a $308.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. HC Wainwright restated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, May 2nd. Oppenheimer upped their target price on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, May 2nd. Finally, Leerink Partnrs restated an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $308.78.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.